Alameda, CA, Apr. 27, 2021 — The article “Tracking adoptive T cell immunotherapy using magnetic particle imaging” has been published in the journal Nanotheranostics (2021, vol 5.). This promising research was concluded using the MOMENTUM™ imager from Magnetic Insight to track the T cells inside a mouse migrating to a brain tumor.
Adoptive T cell immunotherapy has been shown to be an effective treatment for melanomas and blood cancers such as leukemia and lymphoma. However, this therapy has encountered challenges when treating solid tumors such as gliomas, a form of brain cancer. A better understanding of T cell migration to and persistence within solid tumors is necessary to improve the efficacy of these promising immunotherapies.
This work by Angelie Rivera-Rodriguez et al. demonstrates effective non-invasive tracking of adoptive T cells to solid tumors using magnetic particle imaging (MPI). MPI is an emerging technology that quantitatively detects magnetic nanoparticles anywhere in the body. By tagging T cells with a magnetic material, researchers were able to use the MOMENTUM imager from Magnetic Insight to track systemically administered T cells migrating to a brain tumor. The results show that MPI can quantitatively track T cells to solid tumors, providing scientists a new tool for accelerating the development of T cell immunotherapies capable of curing these deadly cancers.
The MOMENTUM imager from Magnetic Insight is a fully integrated and self-shielded pre-clinical MPI solution. The imaging system’s proprietary reconstruction process produces the world’s highest sensitivity and resolution MPI images. The system’s intuitive workflow and robust reconstruction reliably produce high-quality images for pre-clinical research and has laid the groundwork for future advancements in medical imaging products.
The full article can be found in the journal here: https://www.ntno.org/v05p0431.htm.
About Magnetic Insight
Magnetic Insight has pioneered a new diagnostic imaging technology called magnetic particle imaging (MPI) that has the potential to transform medical imaging and healthcare. MPI enables cellular imaging, which goes beyond the structural and metabolic imaging captured by CT, MRI, and nuclear medicine. Having started in the preclinical space by selling small animal products to leading universities around the world, they are now developing a clinical system. For more information visit www.magneticinsight.com.